Advancing innovative vaccine science through collaboration and translational expertise
NIVI‑Development (NIVI‑D) is a mission‑driven organization advancing innovative vaccine science. We bring together leading researchers, vaccine and business developers, and strategic partners to ensure that novel scientific breakthroughs can move swiftly into clinical development.
NIVI-D is part of the Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI) – a unique ecosystem and public-private-partnership that collaborates toward a shared mission.
Advancing research and preparedness to meet current and future respiratory disease threats
Respiratory pathogens are a major public health threat. Airborne diseases spread quickly and unpredictably, and many high‑risk respiratory pathogens still lack vaccines that provide strong, durable protection where it is needed most – in the airways.
New, innovative approaches are required to counteract existing pathogens, as well as new pandemic threats and the rise in antimicrobial resistance. NIVI was created to rise to this challenge and translate research and innovation into new vaccines, better preparedness, and global impact.
A new model for innovation in vaccines and immunity
NIVI brings together leading experts in immunology and vaccine development from Denmark and around the world to develop vaccine candidates against some of the most important and deadly respiratory pathogens. In so doing, NIVI aims to create a knowledge hub in airway immunity and establish vaccine development pipelines that can be rapidly adapted to respond to new emerging pathogens. The three target pathogens for NIVI are influenza, tuberculosis, and group A streptococcus.
NIVI stands out not only for its scientific ambition, but for its structure: a uniquely integrated ecosystem designed to bridge academic discovery and vaccine development.
NIVI-Development (NIVI-D) is a limited liability company owned by the Novo Nordisk Foundation. NIVI-D enables the translational ambitions of NIVI by providing dedicated expertise in vaccine design, streamlined vaccine development, strategic partnerships and alliances, and innovative clinical trials for new vaccine candidates.
NIVI-Research Center (NIVI-R) is an academic research center anchored at the University of Copenhagen that works in close collaboration with Statens Serum Institut as a key partner. NIVI-R is responsible for the research, discovery and educational aspects of the NIVI initiative.
News
February 2026: NIVI Development-coordinated consortium selected by the EU to advance promising pandemic influenza vaccine candidate
A new consortium coordinated by NIVI Development has been selected by the European Commission to run a Phase 1 clinical programme focused on the development of a novel pandemic influenza vaccine candidate.
The consortium comprises seven partners from four EU countries and will evaluate an mRNA‑based vaccine candidate designed to induce mucosal immunity in the airways, the primary entry point for respiratory viruses such as influenza.
The programme aligns with NIVI Development’s mission to develop innovative vaccines with robust, durable, and broad protection against respiratory pathogens, and highlights our collaborative and partnership-driven approach.
Read the full press release here.